Your browser doesn't support javascript.
loading
Ral signaling pathway in health and cancer.
Moghadam, Adel Rezaei; Patrad, Elham; Tafsiri, Elham; Peng, Warner; Fangman, Benjamin; Pluard, Timothy J; Accurso, Anthony; Salacz, Michael; Shah, Kushal; Ricke, Brandon; Bi, Danse; Kimura, Kyle; Graves, Leland; Najad, Marzieh Khajoie; Dolatkhah, Roya; Sanaat, Zohreh; Yazdi, Mina; Tavakolinia, Naeimeh; Mazani, Mohammad; Amani, Mojtaba; Ghavami, Saeid; Gartell, Robyn; Reilly, Colleen; Naima, Zaid; Esfandyari, Tuba; Farassati, Faris.
  • Moghadam AR; Department of Human Anatomy and Cell Science, University of Manitoba, Winnipeg, Canada.
  • Patrad E; Department of Medicine, Molecular Medicine Laboratory, The University of Kansas Medical School, Kansas City, Kansas.
  • Tafsiri E; Department of Pediatrics, Columbia Presbyterian Medical Center, New York, New York.
  • Peng W; Department of Medicine, Molecular Medicine Laboratory, The University of Kansas Medical School, Kansas City, Kansas.
  • Fangman B; Department of Medicine, Molecular Medicine Laboratory, The University of Kansas Medical School, Kansas City, Kansas.
  • Pluard TJ; Saint Luke's Hospital, University of Missouri at Kansas City, Kansas City, Missouri.
  • Accurso A; Department of Medicine, Molecular Medicine Laboratory, The University of Kansas Medical School, Kansas City, Kansas.
  • Salacz M; Department of Medicine, Molecular Medicine Laboratory, The University of Kansas Medical School, Kansas City, Kansas.
  • Shah K; Department of Medicine, Molecular Medicine Laboratory, The University of Kansas Medical School, Kansas City, Kansas.
  • Ricke B; Department of Medicine, Molecular Medicine Laboratory, The University of Kansas Medical School, Kansas City, Kansas.
  • Bi D; Department of Medicine, Molecular Medicine Laboratory, The University of Kansas Medical School, Kansas City, Kansas.
  • Kimura K; Department of Medicine, Molecular Medicine Laboratory, The University of Kansas Medical School, Kansas City, Kansas.
  • Graves L; Department of Medicine, Molecular Medicine Laboratory, The University of Kansas Medical School, Kansas City, Kansas.
  • Najad MK; Department of Medicine, Molecular Medicine Laboratory, The University of Kansas Medical School, Kansas City, Kansas.
  • Dolatkhah R; Department of Medicine, Molecular Medicine Laboratory, The University of Kansas Medical School, Kansas City, Kansas.
  • Sanaat Z; Department of Medicine, Molecular Medicine Laboratory, The University of Kansas Medical School, Kansas City, Kansas.
  • Yazdi M; Department of Medicine, Molecular Medicine Laboratory, The University of Kansas Medical School, Kansas City, Kansas.
  • Tavakolinia N; Department of Medicine, Molecular Medicine Laboratory, The University of Kansas Medical School, Kansas City, Kansas.
  • Mazani M; Pasteur Institute of Iran, Tehran, Iran.
  • Amani M; Ardabil University of Medical Sciences, Biochemistry, Ardabil, Iran.
  • Ghavami S; Pasteur Institute of Iran, Tehran, Iran.
  • Gartell R; Ardabil University of Medical Sciences, Biochemistry, Ardabil, Iran.
  • Reilly C; Department of Human Anatomy and Cell Science, University of Manitoba, Winnipeg, Canada.
  • Naima Z; Department of Pediatrics, Columbia Presbyterian Medical Center, New York, New York.
  • Esfandyari T; Department of Medicine, Molecular Medicine Laboratory, The University of Kansas Medical School, Kansas City, Kansas.
  • Farassati F; Department of Medicine, Molecular Medicine Laboratory, The University of Kansas Medical School, Kansas City, Kansas.
Cancer Med ; 6(12): 2998-3013, 2017 Dec.
Article en En | MEDLINE | ID: mdl-29047224
ABSTRACT
The Ral (Ras-Like) signaling pathway plays an important role in the biology of cells. A plethora of effects is regulated by this signaling pathway and its prooncogenic effectors. Our team has demonstrated the overactivation of the RalA signaling pathway in a number of human malignancies including cancers of the liver, ovary, lung, brain, and malignant peripheral nerve sheath tumors. Additionally, we have shown that the activation of RalA in cancer stem cells is higher in comparison with differentiated cancer cells. In this article, we review the role of Ral signaling in health and disease with a focus on the role of this multifunctional protein in the generation of therapies for cancer. An improved understanding of this pathway can lead to development of a novel class of anticancer therapies that functions on the basis of intervention with RalA or its downstream effectors.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Células Madre Neoplásicas / Proteínas de Unión al GTP ral / Neoplasias Límite: Animals / Humans Idioma: En Año: 2017 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Células Madre Neoplásicas / Proteínas de Unión al GTP ral / Neoplasias Límite: Animals / Humans Idioma: En Año: 2017 Tipo del documento: Article